Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genomic Health Inc Presents Twenty Two International Studies Demonstrating Worldwide Adoption And Value Of Oncotype DX Breast Cancer Test


Friday, 15 Mar 2013 08:00am EDT 

Genomic Health Inc announced the presentation of results from 22 studies at the 13th St. Gallen International Breast Cancer Conference highlighting the impact of the Oncotype DX breast cancer test around the world. New data continue to demonstrate the test's ability to change treatment decisions and provide economic value across multiple health care systems, while reinforcing its clinical validation, accuracy and precision. This unparalleled number of studies and consistency of results emphasize the benefit that the OncotypeDX test provides in breast cancer as the only genomic test shown to predict chemotherapy benefit. A summary of clinical evidence for the Oncotype DX test involving 5,854 patients identified six unique prospectively-designed studies of archived samples that met the strict definition of clinical validation, reinforcing that the Oncotype DX test is the only genomic assay to meet level 1B evidence (Simon RM, Paik S, and Hayes DF. JNCI 2009) for clinical use in early-stage, hormone-receptor positive, invasive, breast cancer patients. Additionally, this analysis includes 11 supportive studies. Decision Impact Data from France, Germany, Israel, Spain, the United Kingdom and United Arabic Emirates Show Oncotype DX Changes Physician Treatment Recommendations. 

Company Quote

26.4
-0.36 -1.35%
12:08pm EDT